J
Jesus Corral
Researcher at University of Navarra
Publications - 55
Citations - 3421
Jesus Corral is an academic researcher from University of Navarra. The author has contributed to research in topics: Lung cancer & Dacomitinib. The author has an hindex of 19, co-authored 51 publications receiving 2694 citations. Previous affiliations of Jesus Corral include Services Hospital & Rafael Advanced Defense Systems.
Papers
More filters
Journal ArticleDOI
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Yi-Long Wu,Ying Cheng,Xiangdong Zhou,Ki Hyeong Lee,Kazuhiko Nakagawa,Seiji Niho,Fumito Tsuji,R. Linke,Rafael Rosell,Jesus Corral,Maria Rita Migliorino,Adam Pluzanski,Eric Sbar,Tao Wang,Jane Liang White,Sashi Nadanaciva,Rickard Sandin,Tony Mok +17 more
TL;DR: Dacomit inib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-positive NSCLC and should be considered as a new treatment option for this population.
Journal ArticleDOI
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Michael Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,E. Laack,Martin Reck,Jesus Corral,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: There was a significant reduction in the risk of disease progression over the placebo group, and the primary endpoint was progression-free survival in the intention-to-treat population.
Journal ArticleDOI
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Mike Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,Eckart Laack,Martin Reck,Jesus Corral,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexing-cisplatin induction therapy.
Journal ArticleDOI
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Tony Mok,Ying Cheng,Xiangdong Zhou,Ki Hyeong Lee,Kazuhiko Nakagawa,Seiji Niho,Min Lee,R. Linke,Rafael Rosell,Jesus Corral,Maria Rita Migliorino,Adam Pluzanski,Eric Sbar,Tao Wang,Jane Liang White,Yi-Long Wu +15 more
TL;DR: In patients with advanced NSCLC and EGFR activating mutations, dacomitinib is the first second-generation epidermal growth factor receptor tyrosine kinase inhibitor (TKI) to show significant improvement in OS in a phase III randomized study compared with a standard-of-care TKI.
Journal ArticleDOI
Identification of proteomic signatures associated with lung cancer and COPD.
Maria Dolores Pastor,Ana Nogal,Ana Nogal,Sonia Molina-Pinelo,Ricardo Melendez,Ana Salinas,M. González De la Peña,José Martín-Juan,Jesus Corral,Rocio Garcia-Carbonero,Amancio Carnero,Luis Paz-Ares +11 more
TL;DR: The protein profiles identified contribute to elucidate the underlying pathogenic pathways of both diseases, and provide new tools of potential use as biomarkers for the early diagnosis of LC.